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allowing exact positioning that is crucial in failing bioprostheses. We
evaluate the acute outcome of degenerated small aortic bioprostheses
treatment with the 23 mm Medtronic CoreValve Evolut R.
METHODS From a total of 560 TAVI performed at our Institute, we
selected 5 consecutive symptomatic patients with degenerated small
aortic bioprostheses showing stenosis, regurgitation or combined
failure. Patients (80  5.5 years) had Logistic EuroSCORE of 29.1  15.8
and STS score of 7.64  6.2. Fast-track general anesthesia with TEE
monitoring was used in all patients. All TAVI were performed by
percutaneous transfemoral access using the 23 mm Medtronic Cor-
eValve Evolut R. After pre-closure with two ProGlide closure devices
(Abbott Vascular), the EnVeo R 14 Fr-equivalent delivery system was
introduced in the common femoral artery and precisely positioned
under ﬂuoroscopic guidance without pre-dilation inside the failed
prostheses. The CoreValve Evolut R was then deployed without
rapid ventricular pacing. Valve recapturing was performed in case of
unsatisfactory positioning with the aim of obtaining minimum pro-
trusion of the CoreValve Evolut R frame below the bioprosthesis
implantation ring.
RESULTS Degenerated stented bioprostheses were one 21-mm Sorin
Mitroﬂow, one 21-mm Carpentier Edwards, one 21-mm Carpentier
Edwards Perimount, and two 19-mm Sorin Mitroﬂow. At MSCT, mean
internal diameter was 17.7 mm. Baseline TTE parameters were: aortic
valve area 0.67  0.17 cm2, peak/mean aortic gradient 69.2  20.3/
44.8  13.4 mmHg; aortic regurgitation was severe in one patient and
moderate in two. After TAVI, aortic valve area increased to 1.34  0.28
cm2, peak/mean aortic gradient decreased to 42.2  12.9/23.8 
6.09 mmHg. Paravalvular leak was mild in three patients and mod-
erate in one. No intra-procedural/in-hospital death, myocardial
infarction, coronary obstruction, stroke and major vascular compli-
cations were observed.
CONCLUSIONS Valve-in-valve treatment of degenerated small aortic
bioprostheses with the CoreValve Evolut R is feasible and safe.
Despite a signiﬁcant increase in aortic area and trans-aortic gradient in
all patients, the mean echocardiographic gradient remained elevated.
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BACKGROUND Self-expanding transcatheter aortic valve replace-
ment (TAVR) is superior to medical therapy for patients with severe
native valve aortic stenosis unsuitable for surgery. Its use in patients
with low-gradient, low output aortic stenosis has not been prospec-
tively studied.
METHODS The CoreValve US Expanded Use Study was a prospective,
non-randomized, single-arm study that evaluated the safety and
effectiveness of TAVR in complex subsets that included extreme risk
patients with low-gradient low output (LGLO) aortic stenosis. LGLO
was deﬁned as Group A: mean gradient < 40 mmHg and peak
velocity < 4 M/sec and resting LVEF  50%, or Group B: mean
gradient < 40 mmHg and peak velocity < 4 M/sec and resting LVEF <
50% who did not augment with dobutamine. These results were
compared with patients enrolled in the Extreme Risk cohort of the US
Pivotal Trial, Group C: mean gradient < 40 mmHg and peak velocity <
4 M/sec and resting LVEF < 50% by resting echo, but who augmented
with dobutamine, and Group D: mean gradient  40 mmHg or peak
velocity  4 M/sec. The primary endpoint was a composite of all-cause
mortality or major stroke rate at 12 months.
RESULTS 189 patients with attempted implant were enrolled between
December 2012 and September 2014 in the Expanded Use Study(Groups A and B). Patients were elderly (81.8  8.7 years), commonly
men (56.6%) and were severely symptomatic (New York Heart Asso-
ciation class III or IV, 89.4%). The STS PROM was 9.9  5.4%. Cor-
eValve diameters included 23 mm (0.5%) 26 mm (22.9%), 29 mm
(39.4%), and 31 mm (37.2%).Group A Group B Group C Group DKM rate (%) or
Mean ± SDN ¼ 136 N ¼ 50 N ¼ 66 N¼ 550Baseline mean
gradient
(mmHg)129.5  4.5 25.1 5.2* 28.8  5.3Ŧ 51.4  12.9ŧBaseline aortic
valve area,
(cm2)10.8  0.2 0.8  0.2 0.7 0.3 0.6  0.2ŧ1 Year all-cause
mortality or
major stroke26.5 27.6 43.9 27.3ŧ1 Year all-cause
mortality22.2 27.6 39.4 25.8ŧ1 Year major
stroke6.7 0.0 11.8Ŧ 4.5ŧN[44 N[16 N[30 N[3351 Year effective
oriﬁce area
(cm2)11.8  0.5 1.9  0.5 1.5  0.4Ŧ 1.7  0.51Site reported data for Groups A and B. Core lab data for Groups C and D. *P<0.05 A vs. B; ŦP<0.05 B vs. C;
ŧP<0.05 C vs. D
CONCLUSIONS The use of CoreValve TAV in LGLO aortic stenosis at
extreme risk for surgery was associated with a low 12-month mortality
rate, and a signiﬁcantly improved aortic valve area that was compa-
rable to the results seen in the Pivotal trial.
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BACKGROUND The combination of severe aortic stenosis (AS) with a
small aortic annulus (SAA) presents a unique challenge to effectively
treat either surgically or percutaneously. The 20mm SAPIEN XT (SXT)
transcatheter heart valve (THV) is currently the smallest of its kind
available for transcatheter aortic valve implantation (TAVI). We report
the initial clinical outcomes and performance of this small THV.
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participating centers in Europe and Canada identiﬁed 36 patients with
SAA who underwent TAVI with the 20mm SXT THV. Baseline and
post-procedural clinical and echocardiographic outcomes were
assessed.
RESULTS Mean age was 846 yrs, with a strong female preponder-
ance (94%). The median (IQR) STS score was 8.7 (5.4, 12.2) %. Baseline
mean aortic gradient, median (IQR) aortic valve area and mean
annular dimensions were 49.517.6 mmHg, 0.50 (0.40, 0.60) cm2 and
18.51.6 mm respectively. Fifteen patients (42%) had a pre-existing
aortic bioprosthesis measuring 19 (n¼6), 21 (n¼8) and 23 (n¼1) mm,
and these patients subsequently underwent valve-in-valve TAVI. The
mean aortic annular diameter, as measured with computed tomog-
raphy, in patients with native AS was 19.11.4 mm. A transfemoral
approach was undertaken in 92% of cases, with successful implanta-
tion in all but 2 patients (6%), with no reports of procedural death,
annular rupture or need for a second valve. Balloon post-dilatation
occurred in 11% of cases. The incidences of in-hospital stroke, major
vascular complication or death were 3, 11, and 6%, respectively.
Overall, post-procedural mean transprosthetic gradient and median
(IQR) valve areas were 17.78.1 mmHg and 1.10 (0.95, 1.30) cm2,
respectively [native AS: 13.25.0 mmHg and 1.22 (1.15, 1.55) cm2;
valve-in-valve: 24.07.5 mmHg and 0.98 (0.77, 1.10) cm2]. Moderate
paravalvular regurgitation was evident in 1 patient.
CONCLUSIONS In patients with severe AS and SAA, TAVI with the
20mm SXT THV is technically feasible, providing satisfactory early
clinical and hemodynamic results, with native valve TAVI yielding
lower post-procedural gradients compared with valve-in-valve TAVI.
Longer-term follow-up in a larger cohort, with clinical and hemody-
namic comparisons against larger THV sizes implanted in corre-
spondingly larger aortic annuli will be necessary to truly ascertain the
feasibility of TAVI in severe AS patients with SAA.
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BACKGROUND Incidence of rhythm changes and permanent pace-
maker implantation post TAVI are variable and may differ depending
on the device type. This report evaluates the incidence and associated
circumstances of the rhythm disturbances observed with the St Jude
Medical Portico Self Expanding TAVI system.
METHODS Rhythm information was collected as part of a prospective,
single arm, multicenter study. Between December 2011 and May 2015,
198 TAVI patients were enrolled and treated at 12 sites in the UK,
Germany, Netherlands, Denmark and Australia using the 18F and 19F
Portico system with a 23mm (50), 25mm (50), 27mm (60) or 29mm (38)
valve size. Rhythm changes during the procedure were recorded at
baseline and at key steps during the implant procedure. Rhythm was
recorded prior to wire passage through the valve, prior to pre-dilata-
tion, immediately post-dilatation, prior to valve crossing, post valve
deployment and at the end of the procedure. Rhythm was recorded
during recovery and at all follow-up intervals.
RESULTS All 198 patients were successfully treated with the Portico
system. The most common rhythm disturbances at baseline were AF
(20%), LBBB (4%), and RBBB (2.5%). A total of 24 patients required a
permanent pacemaker (PPM) post procedure, with complete heart
block as the predominant reason (96%). Depth of implant, valve
resheathing or post dilatation did not appear to impact on the need for
PPM. There were 23 patients (13.5%) who developed a new LBBB
during the procedure, with the majority occurring before valvedeployment (73.9%). An additional 18 patients (11.1%) developed
LBBB before discharge.
CONCLUSIONS The Portico TAVI system demonstrated a low rate of
PPM implantation and induction of new LBBB post TAVI. There does
not appear to be a consistent cause intra-operatively and further
analysis is necessary to understand this phenomenon.
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BACKGROUND Most centers perform transcatheter aortic valve im-
plantation TAVI under general anesthesia (GA) or deep sedation (DS).
TAVI under local anesthesia (LA) might result in less periprocedural
episodes of hypotension, shorter procedure time and hospital stay.
The aim of this study was to compare feasibility and clinical outcome
after TAVI under LA using the self-expandable 18-F-CoreValve pros-
thesis (MCV) versus the 14-20F-balloon expandable Edwards Sapien
XT/3 prosthesis (ESV).
METHODS Between April 2010 and October 2014, 570 consecutive pts
underwent successfully transfemoral TAVI in LA exclusively without
GA or DS receiving either MCV (23/26/29/31mm) or the ESV
(23,26,29mm). Clinical events were evaluated according to the VARC-
II criteria.
RESULTS Patients: 361 pts (age 80.60.34 years) with severe AS
(pmean 43.10.77 mmHg, AVA 0.68  0.01 cm2) and high surgical risk
(log Euroscore 22.0 0.67 %) underwent successfully TAVI with the
MCV and 209 pts (age 81.70.41 years, log Euroscore 18.60.82 %,
pmean 44.21.12 mmHg, AVA 0.68  0.02 cm2) received the ESV
Procedural outcome: Device success was 357/361 (98.9%) for MCV and
208/209 (99.5%) for ESV. Conversion to GA occurred in only 4/361
MCV pts., exclusively for complication (1 coronary obstruction, 2 se-
vere AR, 1 prosthesis embolisation with urgent surgery) and in 0 pts
after ESV. Conversion to DS occurred in 16/361 (4.4%) MCV pts. and in
5/209 (2.4%) ESV pts. Use of vasopressors were needed in 19/361
(5.2%) MCV pts. and in 6/209 (2.9%) ESV pts. In-lab-death and In-lab
stroke rate was 0% in both groups. 30-day clinical outcome: 30 day all-
cause mortality and major/minor stroke rate did not differ signiﬁ-
cantly between valves (death: MCV vs ESV: 5.5% vs 2.4%;
p¼0.052;major stroke: MCV vs ESV: 0.8% vs. 2.4%; P¼0.273. minor
stroke: MCV vs ESV: 0.8% vs. 0.5; p¼0.273.). There was no signiﬁcant
difference between the two valve types concerning major vascular
complication (MCV vs ESV: 4.7% vs. 7.9%; p¼0.082. The rate of new
pacemaker implantation was signiﬁcantly different (MCV vs ESV:
24.4% vs 14.4%, p<0.01).
CONCLUSIONS Transfemoral TAVI using LA only is feasible and save
in an all-comer TAVI-population using either selfexpandable or
balloon-expandable transcatheter heart valves.
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BACKGROUND Transfemoral aortic valve implantation (TAVI) re-
quires large bore catheters. Access site and vascular complications,
